Lynx1 Capital Management’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Lynx1 Capital Management’s Portfolio PRDS Stock Details PRDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-3,902,434	Closed	-$7.06M	–	25
2023 Q2	$7.06M	Buy	3,902,434 +578,373	+17%	+$1.06M	4.63%	7
2023 Q1	$4.39M	Buy	3,324,061 +320,959	+11%	+$525K	3.66%	9
2022 Q4	$5.08M	Buy	3,003,102 +727,370	+32%	+$922K	4.39%	8
2022 Q3	$4.21M	Buy	2,275,732 +95,172	+4%	+$284K	3.8%	7
2022 Q2	$6.69M	Buy	2,180,560 +537,726	+33%	+$3.28M	5.7%	6
2022 Q1	$11.9M	Buy	1,642,834 +1,241,241	+309%	+$12.2M	11.01%	4
2021 Q4	$6.57M	Buy	+401,593	New	+$4.67M	5.74%	6

Other funds holding PRDS

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Lynx1 Capital Management's PRDS Position: Q3 2023 in Review

Lynx1 Capital Management sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q3 2023, closing a stake of 3,902,434 shares — an estimated $7.06M sold.

Lynx1 Capital Management first reported a position in PRDS in Q4 2021 and held it in 7 quarters. The position peaked at $11.9M in Q1 2022. 1 fund tracked by Wall St. Rank holds PRDS as of Q3 2023.

Lynx1 Capital Management reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Lynx1 Capital Management sold 3,902,434 Pardes Biosciences, Inc. Common Stock shares in Q3 2023, an estimated $7.06M.
Lynx1 Capital Management first reported a position in Pardes Biosciences, Inc. Common Stock in Q4 2021 and held it in 7 quarters.
Lynx1 Capital Management's Pardes Biosciences, Inc. Common Stock position peaked at $11.9M in Q1 2022.
1 fund tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q3 2023.

Based on Lynx1 Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.